


IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): A compound having the following formula (I):



wherein

~~R¹ is N-containing heterocyclic ring optionally substituted with one or more suitable substituent(s),~~

~~R² is hydroxyamine,~~







~~R³ is hydrogen or a suitable substituent,~~


~~L¹ is (CH₂)ₙ (wherein n is an integer of 0 to 6) optionally substituted with one or more suitable substituent(s), wherein one or more methylene(s) may be replaced with suitable heteroatom(s), and~~

~~L² is lower alkenylene,~~

~~or a salt thereof~~

R¹ is an N-containing heterocyclic ring represented by the following formula:





wherein

R⁴ is hydrogen or a group selected from the group consisting of:

- (1) lower alkyl optionally substituted with di(lower)alkylamino or hydroxy,
- (2) lower alkoxy,
- (3) aryl optionally substituted with the substituent selected from the group consisting of halogen, lower alkanoyl, lower alkylsulfonyl, lower alkoxy and di(lower)alkylamino,
- (4) lower alkanoyl,
- (5) lower alkoxy-carbonyl,
- (6) arylcarbonyl,
- (7) aryl(lower)alcoxy,
- (8) amino optionally mono- or di-substituted with substituent(s) selected from the group consisting of lower alkyl, lower alkanoyl and cycloalkyl,
- (9) halo(lower)alkyl,
- (10) aryloxy,
- (11) aryl(lower)alkyl optionally substituted with hydroxy,
- (12) carboxyl,
- (13) nitro,
- (14) cyano,
- (15) halogen,
- (16) heteroaryl,
- (17) non-aromatic heterocycle optionally substituted with lower alkyl,

(18) hydroxy,

(19) (lower)alkylsulfonylcarbamoyl and

(20) non-aromatic heterocycle carbonyl;

R⁵ is hydrogen or a group selected from the group consisting of lower alkyl and aryl(lower)alkyl, and

R⁶, R⁷ and R⁸ are each hydrogen or lower alkyl,

R⁹ is hydrogen or a group selected from the group consisting of:

(1) lower alkyl optionally substituted with di(lower)alkylamino,

(2) aryl optionally substituted with lower alkoxy,

(3) (lower)alkoxy-carbonyl,

(4) cyano,

(5) carbamoyl optionally mono- or di-substituted with (lower)alkyl,

(6) halogen,

(7) (lower)alkyl-carbonyl,

(8) arylcarbonyl and

(9) cyclo(lower)alkyl,

R¹⁰ is hydrogen or a group selected from the group consisting of:

(1) (lower)alkylcarbamoyl,

(2) di(lower)alkylcarbamoyl,

(3) aryl optionally substituted with halogen,

(4) (lower)alkoxy-carbonyl,

(5) carboxy,

(6) non-aromatic heterocycle carbonyl,

(7) halogen,

(8) (lower)alkyl optionally substituted with hydroxy, (lower)alkoxy, non-aromatic heterocycle, aryl, di(lower)alkylamino or halogen, and
(9) adamantly;

R¹¹ is hydrogen or aryl(lower)alkyl in which the aryl portion is substituted with lower alkoxy,

R¹² is hydrogen or a group selected from the group consisting of lower alkyl and aryl optionally substituted with halogen,

R¹³ is hydrogen or a group selected from the group consisting of lower alkyl and aryl,

R¹⁴ is hydrogen or lower alkyl,

R² is hydroxyamino,

R³ is hydrogen or lower alkoxy,

L¹ is -(CH₂)_n- (wherein n is 1 to 5) optionally substituted with one or more substituent(s) selected from the group consisting of lower alkyl(s) and aryl(lower)alkyl, and wherein one methylene may be replaced with an oxygen atom, and


L² is vinylene;

or a salt thereof.

Claim 2 (Cancelled)

Claim 3 (Currently Amended): The compound of claim [[2]] 1, wherein


R¹ is an N-containing condensed heterocyclic ring represented by the following formula:



wherein R⁴ and R⁵ are each as defined in claim [[2]] 1.

Claim 4 (Currently Amended): The compound of claim 3, wherein R⁴ and R⁵ are each hydrogen, R² is hydroxyamino, R³ is hydrogen, L¹ is -CH₂-, and L² is vinylene[[,]]; or a salt thereof.

Claim 5 (Currently Amended): The compound of claim [[2]] 1, wherein R¹ is an N-containing heterocyclic ring represented by the following formula:



wherein R⁹, R¹⁰ and R¹¹ are each as defined in claim [[2]] 1.

Claim 6 (Currently Amended): The compound of claim 5, wherein R⁹ is hydrogen or aryl optionally substituted with lower alkoxy, R¹⁰ is hydrogen or aryl optionally substituted with halogen, and R¹¹ is hydrogen, R² is hydroxyamino,




R³ is hydrogen,

L¹ is -CH₂-, and


L² is vinylene[[],];

or a salt thereof.

Claim 7 (Currently Amended): A compound of the following formula:




or



or a salt thereof.

Claim 8 (Currently Amended): A compound having the following formula (I'):



wherein

~~R¹ is N-containing condensed heterocyclic ring optionally substituted with one or more suitable substituent(s),~~

~~R² is hydroxyamino,~~

~~R³ is hydrogen or a suitable substituent,~~



~~L¹ is (CH₂)_n (wherein n is an integer of 0 to 6) optionally substituted with one or more suitable substituent(s), wherein one or more methylene(s) may be replaced with suitable heteroatom(s), and~~

~~L² is lower alkenylene;~~

~~or a salt thereof~~

R¹ is an N-containing condensed heterocyclic ring represented by the following

formula:



wherein

R⁴ is hydrogen or a group selected from the group consisting of

(1) lower alkyl,

(2) lower alkoxy,

(3) aryl optionally substituted with the substituent selected from the group consisting of halogen, lower alkanoyl, lower alkylsulfonyl, lower alkoxy and di(lower)alkylamino,

(4) lower alkanoyl,

(5) lower alkoxy-carbonyl,

(6) arylcarbonyl,

(7) aryl(lower)alkoxy,

(8) amino optionally mono- or di-substituted with substituent(s) selected from the group consisting of lower alkyl, lower alkanoyl and cycloalkyl,

(9) halo(lower)alkyl,

(10) aryloxy,

(11) aryl(lower)alkyl optionally substituted with hydroxy,

(12) carboxyl,

(13) nitro,

(14) cyano,

(15) halogen,

(16) heteroaryl and

(17) non-aromatic heterocycle optionally substituted with lower alkyl,

R⁵ is hydrogen or a group selected from the group consisting of lower alkyl and aryl(lower)alkyl, and

R⁶, R⁷ and R⁸ are each hydrogen or lower alkyl,

R² is hydroxyamino,

R³ is hydrogen or lower alkoxy,


L¹ is -(CH₂)_n- (wherein n is 1 or 2) optionally substituted with one or more substituent(s) selected from the group consisting of lower alkyl(s) and aryl(lower)alkyl, and wherein one methylene may be replaced with an oxygen atom, and

L² is vinylene;

or a salt thereof.

Claim 9 (Cancelled)

Claim 10 (Currently Amended): A compound having the following formula (I''):



wherein

R¹ is N-containing condensed heterocyclic ring optionally substituted with one or more suitable substituent(s),

R² is hydroxyamino,


L¹ is -(CH₂)_n (wherein n is an integer of 0 to 6) optionally substituted with one or more suitable substituent(s), and

L² is lower alkenylene;

or a salt thereof

wherein

R¹ is an N-containing condensed heterocyclic ring represented by the following formula:



wherein

R⁴ is hydrogen or a group selected from the group consisting of lower alkyl and aryl, and

R⁵ is hydrogen or a group selected from the group consisting of lower alkyl and aryl(lower)alkyl,

R² is hydroxyamino,

L¹ is -(CH₂)_n- (wherein n is 1 or 2) optionally substituted with aryl(lower)alkyl, and

L² is vinylene;

or a salt thereof.

Claim 11 (Cancelled)

Claim 12 (Currently Amended): A composition comprising the compound of claim 1 in an amount sufficient to inhibit histone deacetylase inhibitor comprising the compound of claim 1.

Claim 13 (Currently Amended): A pharmaceutical composition comprising the compound of claim 1 in an amount effective for treating or preventing an inflammatory disorder[[s]], diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), organ transplant rejection[[s]], an autoimmune disease[[s]], a protozoal infection[[s]] or a tumor[[s]], which comprises the compound of claim 1.

Claim 14 (Currently Amended): A pharmaceutical composition ~~containing~~
comprising:

the compound of claim 1 as an active ingredient, in association with
a pharmaceutically acceptable, substantially non-toxic carrier or excipient.

Claim 15 (Currently Amended): The composition of claim 14 in a form suitable for
intravenous or intramuscular administration ~~compound of claim 1 for use as a medicament.~~

Claim 16 (Withdrawn): A method for inhibiting histone deacetylase, comprising
using the compound of claim 1.

Claim 17 (Withdrawn): A method for treating or preventing an inflammatory
disorder[[s]], diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis,
acute promyelocytic leukaemia (APL), an organ transplant rejection[[s]], an autoimmune
disease[[s]], a protozoal infection[[s]] or a tumor[[s]], which comprises administering an
effective amount of the compound of claim 1 to a subject in need thereof ~~human being or an~~
~~animal.~~

Claim 18 (Currently Amended): A commercial package comprising:
the pharmaceutical composition of claim 13 and
a written matter associated therewith, the written matter stating that the
pharmaceutical composition may or should be used for treating or preventing an
inflammatory disorder[[s]], diabetes, diabetic complications, homozygous thalassemia,

fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), an organ transplant rejection[[s]], an autoimmune disease[[s]], a protozoal infection[[s]] or a tumor[[s]].

Claim 19 (Currently Amended): A composition comprising the compound of claim 7 in an amount sufficient to inhibit histone deacetylase inhibitor comprising the compound of claim 7.

Claim 20 (Currently Amended): A pharmaceutical composition comprising an amount of the compound of claim 7 effective for treating or preventing an inflammatory disorder[[s]], diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), organ transplant rejection[[s]], an autoimmune disease[[s]], a protozoal infection[[s]] or a tumor[[s]], which comprises the compound of claim 7.

Claim 21 (Currently Amended): A pharmaceutical composition containing comprising:

the compound of claim 7 as an active ingredient, in association with a pharmaceutically acceptable, substantially non-toxic carrier or excipient.

Claim 22 (Currently Amended): The compound of claim 7 composition of claim 20 in a form suitable for intravenous or intramuscular administration for use as a medicament.

Claim 23 (Withdrawn): A method for inhibiting histone deacetylase, comprising using the compound of claim 7.

Claim 24 (Withdrawn): A method for treating or preventing an inflammatory disorder[[s]], diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), organ transplant rejection[[s]], an autoimmune disease[[s]], a protozoal infection[[s]] or a tumor[[s]], which comprises administering an effective amount of the compound of claim 7 to a subject in need thereof human being or an animal.

Claim 25 (Currently Amended): A commercial package comprising:
the pharmaceutical composition of claim 20, and
a written matter associated therewith, the written matter stating that the pharmaceutical composition may or should be used for treating or preventing an inflammatory disorder[[s]], diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), an organ transplant rejection[[s]], an autoimmune disease[[s]], a protozoal infection[[s]] or a tumor[[s]].

Claim 26 (Currently Amended): A composition comprising the compound of claim 8
in an amount sufficient to inhibit histone deacetylase inhibitor comprising the compound of
claim 8.

Claim 27 (Currently Amended): A pharmaceutical composition comprising the
compound of claim 8 in an amount effective for treating or preventing an inflammatory disorder[[s]], diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), an organ transplant rejection[[s]], an autoimmune disease[[s]], a protozoal infection[[s]] or a tumor[[s]], which comprises the compound of claim 8.

Claim 28 (Currently Amended): A pharmaceutical composition ~~containing~~
comprising:

the compound of claim 8 as an active ingredient, in association with
a pharmaceutically acceptable, substantially non-toxic carrier or excipient.

Claim 29 (Currently Amended): The composition of claim 27 in a form suitable for
intravenous or intramuscular administration ~~compound of claim 8 for use as a medicament.~~

Claim 30 (Withdrawn): A method for inhibiting histone deacetylase, comprising
using the compound of claim 8.

Claim 31 (Withdrawn): A method for treating or preventing an inflammatory
disorder[[s]], diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis,
acute promyelocytic leukaemia (APL), an organ transplant rejection[[s]], an autoimmune
disease[[s]], a protozoal infection[[s]] or a tumor[[s]], which comprises administering an
effective amount of the compound of claim 8 to a subject in need thereof ~~human being or an~~
~~animal.~~

Claim 32 (Currently Amended): A commercial package comprising:
the pharmaceutical composition of claim 27 and
a written matter associated therewith, the written matter stating that the
pharmaceutical composition may or should be used for treating or preventing an
inflammatory disorder[[s]], diabetes, diabetic complications, homozygous thalassemia,

fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), an organ transplant rejection[[s]], an autoimmune disease[[s]], a protozoal infection[[s]] or a tumor[[s]].

Claim 33 (Currently Amended): A composition comprising the compound of claim 10 in an amount sufficient to inhibit histone deacetylase inhibitor comprising the compound of claim 10.

Claim 34 (Currently Amended): A pharmaceutical composition comprising the compound of claim 10 in an amount effective for treating or preventing an inflammatory disorder[[s]], diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), an organ transplant rejection[[s]], an autoimmune disease[[s]], a protozoal infection[[s]] or a tumor[[s]], which comprises the compound of claim 10.

Claim 35 (Currently Amended): A pharmaceutical composition containing comprising:

the compound of claim 10 as an active ingredient, in association with a pharmaceutically acceptable, substantially non-toxic carrier or excipient.

Claim 36 (Currently Amended): The composition of claim 33 in a form suitable for intravenous or intramuscular administration compound of claim 10 for use as a medicament.

Claim 37 (Withdrawn): A method for inhibiting histone deacetylase, comprising using the compound of claim 10.

Claim 38 (Withdrawn): A method for treating or preventing inflammatory disorders, diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), organ transplant rejections, autoimmune diseases, protozoal infections or tumors, which comprises administering an effective amount of the compound of claim 10 to a human being or an animal.

Claim 39 (Currently Amended): A commercial package comprising:
the pharmaceutical composition of claim 34, and
a written matter associated therewith, the written matter stating that the pharmaceutical composition may or should be used for treating or preventing an inflammatory disorder[[s]], diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), an organ transplant rejection[[s]], an autoimmune disease[[s]], a protozoal infection[[s]] or a tumor[[s]].